Iconovo

Iconovo Net Margin

The Net Profit Margin of Iconovo (ICO.ST) as of Oct 30, 2026 is -3,924.34 %. In the previous year, Net Profit Margin was -1,402.18 % — a change of 179.87% (lower).

Net Margin

-3,924.34 %

YoY

179.87%

Last updated:

Net Profit Margin of Iconovo is 2025 -3,924.34 % . Net Profit Margin of Iconovo was 2024 -1,402.18 % . It decreases by 179.87% lower compared to the previous year.

For Iconovo, the net margin of -3,924.3% is down versus -169.8% a few years ago.

The Iconovo Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-36.06 SEK
Jan 1, 2019
-93.77 SEK
Jan 1, 2020
-96.30 SEK
Jan 1, 2021
-169.77 SEK
Jan 1, 2022
-293.93 SEK
Jan 1, 2023
-648.37 SEK
Jan 1, 2024
-1,402.18 SEK
Jan 1, 2025
-3,924.34 SEK
The Iconovo Net Margin history
YEARNet MarginYoY
-3,924.34 %+179.87%
-1,402.18 %+116.26%
-648.37 %+120.59%
-293.93 %+73.13%
-169.77 %+76.29%
-96.30 %+2.70%
-93.77 %+160.01%
-36.06 %-598.21%
7.24 %-57.71%
17.12 %-102.86%
-599.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Iconovo Stock analysis

What does Iconovo do? Iconovo AB generates revenue through the development, manufacturing, and supply of inhalation products. The company offers device platforms including ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices, and ICOpre, which are part of its device family. Iconovo also provides development programs for generic inhalation products based on therapeutic equivalence, as well as development for inhalation products using generic API and new chemical entity (NCE) applications. These services are targeted at pharmaceutical companies seeking to develop inhalation therapies, particularly for generic and innovative drug delivery systems. The company’s solutions include formulation, analytical testing, and documentation services tied to its device platforms. Iconovo AB’s product portfolio supports the development of pre-metered devices like ICOpre and capsule-based devices such as ICOcap, which are used in respiratory treatment applications. Its clinical trial programs, such as phase I-II trials using ICOone, cater to pharmaceutical clients requiring early-stage development support for inhalation products. Iconovo AB’s business model focuses on providing end-to-end solutions for inhalation product development, from formulation to clinical trials. The company serves pharmaceutical manufacturers who need to bring inhalation therapies to market, leveraging its device platforms and development expertise. Its offerings are structured around specific device types and development pathways, ensuring tailored support for both generic and novel inhalation product launches. Iconovo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Iconovo stock

Net Profit Margin of Iconovo is -3,924.34 % in 2025.

Net Profit Margin of Iconovo changed from -1,402.18 % to -3,924.34 %, representing a 179.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Iconovo since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Iconovo with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Iconovo

All Key Metrics — Iconovo